about
Chemokine expression in IBD. Mucosal chemokine expression is unselectively increased in both ulcerative colitis and Crohn's disease.Concentrations of interleukin 6 and tumour necrosis factor in serum and stools of children with Shigella dysenteriae 1 infection.Artificial liver support in acute liver failure: a review of studies at King's.Sudden unexpected death in alcohol misuse--an unrecognized public health issue?Priority actions for the non-communicable disease crisis.Are the opportunities to prevent alcohol related liver deaths in the UK in primary or secondary care? A retrospective clinical review and prospective interview studyHepatocyte expression of the senescence marker p21 is linked to fibrosis and an adverse liver-related outcome in alcohol-related liver diseaseEvaluation of work-based screening for early signs of alcohol-related liver disease in hazardous and harmful drinkers: the PrevAIL study.The alcohol harm paradox: using a national survey to explore how alcohol may disproportionately impact health in deprived individuals.Hepatic changes in the failing Fontan circulation.Alcohol-related harm--a growing crisis: time for action.Alcohol: who is at risk?Feasibility of detection and intervention for alcohol-related liver disease in the community: the Alcohol and Liver Disease Detection study (ALDDeS).Profits and pandemics: prevention of harmful effects of tobacco, alcohol, and ultra-processed food and drink industries.Current treatment options for alcohol-related liver disease.Interferon therapy in hepatitis B virus infection.Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis.Alcoholic liver disease - the extent of the problem and what you can do about it.Alcohol and liver disease in Europe--Simple measures have the potential to prevent tens of thousands of premature deaths.Should we screen for cirrhosis?A rapid evidence review of the effectiveness and cost-effectiveness of alcohol control policies: an English perspective.Temporary sequential atrioventricular pacing in myocardial infarction.New metrics for the Lancet Standing Commission on Liver Disease in the UK.Projections of alcohol deaths--a wake-up call.Trends in European liver death rates: implications for alcohol policy.Assessing feasibility and acceptability of a brief intervention for risky alcohol consumption in sexual health clinic attendees: a randomised controlled trial.Effect of policy, economics, and the changing alcohol marketplace on alcohol related deaths in England and Wales.Exercise-Induced Systemic Venous Hypertension in the Fontan Circulation.A drunk and disorderly country: a nationwide cross-sectional survey of alcohol use and misuse in Great Britain.Impact of minimum price per unit of alcohol on patients with liver disease in the UK.Reducing the harms of alcohol in the UKRenal hepatitis C in the absence of detectable serum or hepatic virus.Social inequalities in alcohol-related adult mortality by National Statistics Socio-economic Classification, England and Wales, 2001-03.TNF alpha in stool as marker of intestinal inflammation.An evidence-based alcohol policy.Binge drinking, sexual behaviour and sexually transmitted infection in the UK.Severe alcohol-induced liver disease and the alcohol dependence syndrome.Alcohol in Europe: the EU alcohol forum.Regulation of interleukin-8 binding and function by heparin and alpha2-macroglobulin.Sexual assault and coincident alcohol use in attendees at a genitourinary medicine clinic in the south of England.
P50
Q30873571-CD180235-8EE0-447D-8137-17B7A6C48BF2Q33494319-B1756C6A-8F22-4478-BF29-EAE3303CE212Q33541444-29F45B53-163D-47DA-A7A3-A4BF5F8E4BB4Q33566940-C792E6BD-A06F-4594-A064-33B19E365EB3Q34176583-29D78931-504C-46A0-857F-BE995396458EQ34805898-2D37C320-1C92-49CB-9B3B-19CC0524CF87Q35004683-61B11DDE-D6B9-45A9-A61C-A7C4AC7EDA2DQ35652190-895BDF67-5DCB-47D8-A4A2-3999A839EE51Q35926835-C460ABF4-7044-42F4-A0D8-DC92AEBF1985Q35956151-4A9DC628-43EB-4774-8B8C-D93E71FC53C5Q36104761-595711DA-9CC5-446D-B08F-B11DCDB63902Q36291938-5677DD9D-7AF3-4BAF-94CF-EAAB98055722Q37196842-D8F98639-AD0C-4772-B8C0-3B16F56C8790Q38081564-FBC195F7-2099-4E05-87AD-9FAED9D0F88BQ38198914-CE5BF99C-0775-476C-B8DE-3DA76A1FD9DEQ38205726-3CEBF9CD-5681-49D1-B3E3-0FFA1D8791D0Q38272635-AD78CAD7-7917-421C-8BF1-E46F56F3BFB6Q38396377-CC137DAE-9D8B-4ACA-8900-DED7C9B262D3Q38642337-793F4452-CF08-4122-8261-CAFBB8D98CD9Q38682099-2695276A-FF19-4017-86CC-6E8E4EEA0C80Q39029769-316DE83A-FA3F-4C9A-BCCB-B0BAFFF05151Q39167287-B497F05C-780F-4580-A5A6-B7B69A022BE7Q39595721-02DB508B-CE90-4CA0-B1E1-5BACDDEA1200Q39781124-3DF5B085-A4B9-46B2-BDE9-F0B16DA318F4Q39946963-B15227B1-B477-402D-9C2A-79F8B3186224Q40304163-62696032-E6F9-4AA4-B215-E6BBAC958BECQ40814327-2D66DBE5-1F92-4F73-B45B-73FAE70B3743Q40824177-8EB936B4-50A2-4FDD-A439-7FB28A19D9B3Q41060465-D5298A3A-6023-451A-9B4C-439388C1C6DCQ42202932-367D3767-BBB6-4501-8E8F-B9C7872F6DEBQ42860596-DC5FB7B1-A783-46FB-BEAE-05452590E59AQ42980197-2CDEF21E-0755-4EE3-852F-D69C26F97BB1Q43653225-C9986956-2E50-4C3F-9B1D-7EB2EB4F6A89Q44517632-BA629C80-C06F-4761-B561-98E5E67F6806Q46619964-50DDC7A7-29A9-490C-A03F-80EF6855F01AQ46855683-E2462BF9-5F08-462E-8EDC-494698A03D2BQ46979748-33AEAE65-E111-4006-9B16-E20A65A21458Q46990870-D52DF636-E6C3-4524-AF90-8643078A36D9Q47914730-33F16126-A389-4C58-A33D-AE3F267B780AQ48014680-18185C74-3331-42D6-A2AB-0574DCEBD309
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Nick Sheron
@ast
Nick Sheron
@en
Nick Sheron
@es
Nick Sheron
@nl
Nick Sheron
@sl
type
label
Nick Sheron
@ast
Nick Sheron
@en
Nick Sheron
@es
Nick Sheron
@nl
Nick Sheron
@sl
prefLabel
Nick Sheron
@ast
Nick Sheron
@en
Nick Sheron
@es
Nick Sheron
@nl
Nick Sheron
@sl
P106
P21
P31
P496
0000-0002-6156-8367